Geographic Atrophy

HTML clipboard

With the increasing prevalence and retinal disease unmet clinical needs - what drug Lucentis will be next?

The overall prevalence of AMD (macular degeneration) and diabetic retinopathy are increasing because of growing number of elderly people in the world. In addition, the world is facing a diabetes epidemic ", with rapidly increasing numbers of people with diabetes and diabetic retinopathy. A clear market opportunity exists for pharmacological treatments for diabetic retinopathy, dry AMD and other retinal diseases. From 2009 to 2024, these treatments may repeat the commercial success that Lucentis in the treatment of wet AMD. Our latest report Pharma - World AMD and diabetic retinopathy Pharmaceutical Market 2009-2024 - examines outlook for the market of retinal disorders in the next 15 years. ( http://www.bharatbook.com/Market-Research-Reports/World-AMD--and-diabetic retinopathy-pharmaceutical-market-2009-2024. html )

The quick sales of Lucentis in treating wet AMD shows the height of the profits for selling novel treatments on the market for retinal disorders. There is a clear market opportunity for other drugs to treat diabetic retinopathy, a disease for which there is currently no approved pharmacological treatment. Our analysts believe that there are still market opportunities for new treatments of geographic atrophy (advanced dry AMD) and wet AMD. It is necessary to clear advantages over existing therapies wet AMD in order to improve clinical outcomes and ease of administration. This report analyzes the prospects for the future.

Comprehensive analysis of the market area

World AMD and diabetic retinopathy Pharmaceutical Market 2009-2024 examines this critical sector, through a thorough examination of information sources, both primary and secondary. This report provides detailed forecasts on sales, discussions on the development pipeline and analysis of commercial drivers and restraints, including SWOT analysis. There are over 55 tables and figures and three full interviews with experts in the sector. The result is a global market and industry report focuses, with detailed analysis and informed opinion in favor of your work.

Why you should buy AMD and diabetic retinopathy World Pharmaceutical Market 2009-2024

You will receive the following benefits when you order this report:
aec You will receive sales forecasts for the market of retinal disorders worldwide, AMD's market, the market for diabetic retinopathy and the market for other diseases of the retina, with sales forecasts for leading brands of 2009-2024
aec You will read the expert opinion of key opinion leaders in diseases of the retina pharmaceutical sector, including transcripts of interviews not published elsewhere
aec You will gain a comprehensive assessment of strengths, weaknesses, opportunities and threats for this sector, including discussion of market drivers and restraints
aec You will receive a review of prospects to Lucentis in the face of competition from off-label use of Avastin, with the support of market forecasts
aec You will get a regional analysis of AMD and diabetic retinopathy markets, with sales forecast
aec You will receive in-depth analysis of the pharmaceutical pipeline for AMD, diabetic retinopathy and other retinal diseases.

Contact us at:

Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: